Abivax announces a change to the composition of its board of directors

Abivax announces a change to the composition of its board of directors paris, france, december 23, 2024, 10:05 pm cest – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that dr. philippe pouletty, representative of truffle capital, tendered his resignation as director of the company effective on december 31, 2024. dr. philippe pouletty's decision is directly related to his appointment last week as chairman and acting chief executive officer of a french listed biotechnology company in the field of plastics recycling.
ABVX Ratings Summary
ABVX Quant Ranking